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Abstract: 
 
In our search for potential antihypertensive agents, a series of structurally-related flavonoids was 
screened. Ex vivo and in vitro biological evaluations indicated that compounds 1–7 displayed an 
important vasorelaxant effect on the endothelium-intact (E+) and -denuded (E−) aortic rings test. 
Their in vitro anti-calmodulin (CaM) properties were determined by means of the inhibitory 
effect on the activation of the calmodulin-sensitive cAMP phosphodiesterase (PDE1) assay. 
Molecular modeling experiments were also performed in order to explore the probable binding 
site of 1–7 with CaM, and the results indicated that they could bind to the protein in the same 
pocket as trifluoperazine (TFP), a well-known CaM inhibitor. 
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Article: 
 
1. Introduction 
 
Hypertension, one of most common cardiovascular diseases, is defined as repeatedly elevated 
systolic and/or diastolic blood pressure above 140/90 mm Hg.2 Several antihypertensive drugs 
used in the treatment of this disease, including diuretics, sympatholytics, vasodilators, and 
calcium channel and angiotensin blockers; accomplish their activity through four main effectors 
sites: resistance and capacitance vessels, heart, and kidney.3 In addition, compounds with 
significant activity on smooth muscle cells might also act as direct vasodilator agents by means 
of the production of some second messengers, for example, nitric oxide (NO), cyclic guanosine 
monophosphate (cGMP), prostacyclin PGI2, or cyclic adenosine monophosphate (cAMP). 
Finally, the protein calmodulin (CaM), a major cellular Ca2+-binding protein which regulates the 
activity of a series of CaM-dependent enzymes such as NO synthases, phosphodiesterases 
(PDE’s), adenylate cyclases, phosphatases, several kinases, ion channels, calcium-ATPase 
pumps, among others, represent an important molecular target for the development of new leads 
that could be used as antihypertensive agents.4, 5, 6, 7 
 
Flavonoids are a diverse group of secondary metabolites well-known for having a range of 
human health-promoting activities such as antiinflammatory, antioxidant, vasodilating, 
antiallergenic, antiviral, antidiabetic, antidiabetogenic, and anticancer properties.8, 9, 10, 11, 12 
However, this group of compounds has never been studied or used in the therapeutic for the 
treatment of hypertension. 
 
In an attempt to find novel antihypertensive drugs from medicinal plants, here we report the ex 
vivo and in vitro vasorelaxant effect of a series of structurally-related flavonoids, using the aorta 
rat rings pre-contracted model. In addition, to provide detailed information about the possible 
mechanism of action of these metabolites through the Ca2+-CaM complex inhibition, a series of 
in vitro enzymatic and in silico experiments were conducted. 
 
2. Results and discussion 
 
A series of seven known flavonoids, flavone (1), 3-hydroxyflavone (2), 6-hydroxyflavone (3), 7-
hydroxyflavone (4), chrysin (5), quercetin (6), and naringenin (7) (Fig. 1), were subjected to a 
series of ex vivo and in vitro vasorelaxant and CaM-Ca2+-PDE assays, as well as in silico 
docking experiments. Flavonoids 1−6 showed a significant vasorelaxant activity, in a 
concentration-dependent manner, on the contraction activity induced by noradrenaline (0.1 μM, 
NA) (Fig. 2). Compounds 1, 3, and 4 were the most potent, and revealed a partial endothelium-
dependent effect (Fig. 2 and Table 1). The latter suggests that endothelium-derived factors such 
as NO or prostacyclin PGI2 are involved on the activity of these compounds.11 In contrast, an 
endothelium-independent relaxation is related with a smooth muscle cells activity, which 
interferes on contraction processes such as α-adrenoceptors antagonism, calcium channel 
blockade, potassium channel opening, cAMP or cGMP increment, or Ca2+-CaM complex activity 
inhibition.7, 13 
 
 
Figure 1. Structurally-related flavonoids studied. 
 
 
Figure 2. Concentration-dependent vasorelaxant effect of compounds 1–7 on the endothelium-
intact (E+) or -denuded (E−) aortic rings test. 
 
In previous works, Ajay and co-workers described that compounds 1 and 6 showed an 
endothelium-dependent vasorelaxant effect, with an NO and prostacyclin PGI2 increase 
production.14 Also, compound 7 induced vasorelaxant effect through NO production, PDE 
inhibition, and K+ channel opening.14, 15, 16, 17 On the other hand, Calderone and co-workers 
demonstrated that compounds 3 and 4 induced a vasorelaxant effect, in a concentration-
dependent manner, on an endothelium-independent model, attributed to a K+ channel opening.18 
In this context, compound 3, the most active compound in the functional vasorelaxant assay, was 
subjected to a series of experiments to determine its mechanism of action. The pre-incubation of 
endothelium-denuded aortic rings with chlorpromazine (CPZ), a well-known CaM inhibitor used 
as a positive control, significantly increase the activity of 3, which is showed as a left shift in the 
vasorelaxant effect curves (Fig. 3). This effect suggests a possible Ca2+-CaM complex inhibition 
by 3, and is consistent with the significant endothelium-independent relaxation on aortic rings 
pre-contracted with NA, previously observed by hesperidin, which inhibited the formation of the 
complex CaM-Ca2+-PDE1 and -PDE4 isolated from bovine aorta with IC50 values of 74 and 
70 μM, respectively.7 
 
Table 1. Vasorelaxant effect and anti-CaM properties of compounds 1–7 
Compound Ex vivo vasorelaxant effect Ca2+-CaM-PDE1 inhibition 
IC50 (μM) Emax relaxation (%) IC50 (μM)c Potencyd 
Cambiar por E+a Cambiar por E−b E+a E−b   
1 46.00 203.00 98.64 80.97 102.28 ± 26.90 0.34e 
2 203.60 248.30 67.77 29.80 55.20 ± 16.87 0.36f 
3 20.80 112.37 104.57 51.84 5.17 ± 1.36 3.89f 
4 37.80 167.04 80.59 40.39 37.10 ± 5.74 0.54f 
5 75.70 106.90 44.75 16.00 33.43 ± 6.46 1.03e 
6 162.50 222.47 83.23 43.18 12.97 ± 1.35 2.82e 
7 NDg NDg NDg NDg 22.01 ± 3.02 0.91f 
Carbacholh 0.79 NDg 88.62 NDg NDg NDg 
Nifedipinei NDg 0.02 NDg 102.17 NDg NDg 
a E+: endothelium-intact aortic rings. 
b E−: endothelium-denuded aortic rings. 
c Values as means ± SEM, n = 6, p <0.05. 
d Potency was obtained by the formula: IC50 (μM) CPZ/IC50 (μM) compound, assuming a value of 1.00 for CPZ. 
e IC50 μM of CPZ = 34.57 ± 1.59. 
f IC50 μM of CPZ = 20.1 ± 3.13. 
g ND: Not determined. 
h Positive control for experiments with E+. 
i Positive control for experiments with E−. 
 
 
Figure 3. Concentration-dependent vasorelaxant effect of compound 3 on the endothelium-intact 
(E+) or -denuded (E−) aortic rings pretreated with CPZ (1 μM). 
 
Thus, the effect of 1–7 on a human recombinant-CaM was initially assessed in vitro, using the 
CaM-sensitive cAMP phosphodiesterase (PDE1) as a monitoring enzyme.19, 20 This functional 
experiment is commonly employed to detect CaM antagonists.20, 21, 22 The results showed in 
Table 1 revealed that all flavonoids inhibited the activation of PDE1 in a concentration-
dependent manner; compounds 3 (IC50 = 5.17 ± 1.36 μM) and 6 (IC50 = 12.97 ± 1.35 μM) were 
the most active, while 5 (IC50 = 33.43 ± 6.46 μM) and 7 (IC50 = 22.01 ± 3.02 μM), displayed a 
moderate activity comparable to that of CPZ. 
 
CaM binding sites has been subjected to several in silico studies. Recently, Li and collaborators 
reported the interaction of the phosphorylated flavonoid chrysin with CaM using docking and 
molecular dynamic analyses.23 Two different favorable binding modes were observed; the most 
favored binding pocket consisted of the amino acids Ala57, Asp58, Pro66, Glu67, Thr70, Arg74, 
Met76, Lys77, Asp78, Thr79, Asp80, and Glu82, and the molecule was tethered to the CaM by 
several hydrogen bonds. The putative interaction of several xanthones and alkaloids has also 
been studied, and the binding sites predicted were close-related to those for the classical CaM 
inhibitors trifluoperazine (TFP) and CPZ.19, 20, 24, 25 In this context, in order to gain better 
understanding of the interaction of flavonoids 1–7 with CaM, molecular docking studies were 
performed. Briefly, the validated docking protocol employed adequately predicts the binding 
mode of TFP, which was removed from the active site and docked back into pocket, in the 
conformation found in its CaM crystal structure (Protein Data Bank code: 1A29).20, 23 CPZ 
docking was also validated. 
 
For compounds 1–7, the best docking pose revealed a well fitting into the same pocket of TFP 
and CPZ, the active cavity of CaM (Fig. 4a). The calculated free binding energies values (EFEB) 
for 1−7, are in the range of −5.5 and −7.0 kcal/mol (Table 2), and are comparable with those of 
CPZ (−6.9 kcal/mol), but higher than TFP (−10.5 kcal/mol). In addition, the following 
preliminary structure-in silico activity could be done: (a) compounds bearing substituent at 
position C-3 of the C ring of the flavone core have the lowest calculated free energies (2 and 6); 
(b) compounds bearing one or none substituent at positions 3, 5 or 7 displayed similar free 
energies (1–4), having 4 the relatively lowest free energy; and (c) compounds having two 
hydroxyl groups at positions 5 and 7 in the A ring displayed similar free energies (5 and 7). For 
instance 3 and 6, with IC50 values of 5.17 ± 1.36 and 12.97 ± 1.35 μM, respectively, exhibited 
the lowest free energy values of −6.24 and −7.01 kcal/mol, respectively, being both compounds 
the most potent. Besides the fact that the lipophilic and hydrophilic residues in this active site are 
one of the most important characteristics in favor to their electrostatic interaction with the 
receptor, and, as shown in Figure 4b, compounds 3 and 6 are inserted into a pocket surrounded 
by the residues Glu7, Glu11, Phe92, Ile100, Leu105, Met109, Met124, Ile125, Glu127, Val136, 
Phe141, Met144, Met145, and Ala128. In addition, hydrogen bonds have been also formed with 
the receptor at Glu7, Glu11, and Glu127 (<5 Å distance). Finally, hydrophobic π–π interaction 
are also seen between the dihydroxyphenyl or aromatic ring of 3 and 6, with Phe92 and Phe141 
residues (Fig. 4b), as well as the hydrophobic interactions with the Met residues. In overall, the 
same behavior has been demonstrated for the classical drugs TPZ and CPZ. 
 
 
Figure 4. (a) Best docking score conformations of compounds 1–7 (green, brown, yellow, olive, 
orange, cyan, and blue, respectively, sticks) into CaM (surface). TFP X-ray crystal pose is shown 
as balls and sticks (magenta). (b) Residues involved in the interaction of compounds 3 (yellow) 
and 6 (cyan) with CaM (carbon atoms in grey, oxygen in red, nitrogen in blue, and sulfur in pale 
yellow sticks). Dashed green lines are the intermolecular hydrogen (H)-bonds. Images were 
created by PyMol l.3. 
 
Table 2. Calculated free binding energies (EFEB) with autodock 4.0 for compounds 1–7, CPZ 
and TFP 
Compound EFEB (kcal/mol) 
1 −6.08 
2 −6.07 
3 −6.24 
4 −6.08 
5 −5.74 
6 −7.01 
7 −5.55 
TFP −10.49 
CPZ −6.90 
 
3. Conclusions 
 
In summary, a series of structurally-related flavonoids studied in the present investigation 
showed an important vasorelaxant effect on the endothelium-denuded aortic rings test. Their 
anti-CaM properties demonstrated by both ex vivo and in vitro experiments, were confirmed by 
the in silico analysis, allowed us to establish that this category of secondary metabolites have a 
potential for further development as novel antihypertensive agents. 
 
4. Experimental 
 
4.1. Chemicals 
 
All chemicals were ACS grade; flavone (1), 3-hydroxyflavone (2), 6-hydroxyflavone (3), 7-
hydroxyflavone (4), chrysin (5), quercetin (6), and naringenin (7) were purchased from Sigma-
Aldrich Chemical Co. (St. Louis, MO). For the ex vivo and in vitro experiments all compounds 
were dissolved with DMSO, and then diluted with distilled water. 
 
4.2. Animals 
 
All the animals were conducted according to the Mexican Official Norm for Animal Care and 
Handing (NOM-062-ZOO-1999) and in compliance with International Guidelines on Care and 
Use of Laboratory Animals. Furthermore, clearance for conducting the studies was taken from 
the Ethics Committee for the Use of Animals in Pharmacological and Toxicological Testing. 
Wistar rats weighing between 200 and 300 g were fed a standard rodent diet ad libitum with free 
access to water and maintained under standard laboratory conditions (12 h light/dark cycle, 
25 °C and humidity of 45–65%). 
 
4.3. Rat aorta ring assay 
 
The vasorelaxant activity was performed using a modified standard protocol of Saponara and co-
workers.16 All animals were sacrificed by cervical dislocation and the thoracic aorta was 
removed, cleaned, and cut in about 3–5 mm length rings. In addition, for some aortic rings the 
endothelium layer was removed by manual procedures. Then, each piece of tissue was suspended 
in a tissue chamber containing Krebs solution at 37 °C, continuously gassed with O2/CO2 (9:1). 
Tissues were placed under a resting tension of 3.0 g and allowed to stabilize for 60 min. The 
contractions were recorded with an isometrical force transducer Grass FT 03 (Astromed, West 
Warwick, RI), connected to a MP100 Manager Biopac System polygraph (Biopac Instruments, 
Santa Barbara, CA). After the stabilization period the tissues were stimulated with NA (0.1 μM) 
during 10 min and they were washed with fresh Krebs solution. This procedure was repeated 
three times at 30 min intervals before starting the experiments. The absence or presence of 
endothelium layer was confirmed by the lack of the relaxant response induced by carbachol 
(1 μM) in the last contraction to assess viability. Finally, all tissues were contracted with NA and 
test samples (pure compounds or positive control) were added to the bath in quarter-log 
cumulative concentrations (evaluation period). The relaxant effect of the samples was 
determined by its ability to induce a maximal vascular contraction before and after their addition. 
 
Next, in order to obtain evidence of the vasorelaxant mode of action exerted by compound 3, an 
additional analysis with CPZ, a well know CaM inhibitor, was assessed using 1 μM of CPZ in 
the presence or absence of 3. 
 
4.4. Phosphodiesterase activity 
 
Phosphodiesterase activity was measured according to the method described by Figueroa and co-
workers.20 CaM (0.08 μg) was incubated with 0.015 units of PDE1 from bovine brain during 
30 min in 40 μL of assay solution containing 0.063 units of 5′-nucleotidase (Crotalus 
atrox venom from Sigma), 45 mM Tris–HCl, 5.6 mM magnesium acetate, 45 mM imidazole, 
2.5 mM calcium chloride, and 10 μM BSA, pH 7.0. Test compounds were then added to the 
assay medium at 0.5, 1, 2, 3, 4, 7, 13, 20, 32, 50, and 65 μM in ACN/water (1:1), and the 
samples incubated during 30 min; thereafter 10 μL of 10.8 mM cAMP were added to start the 
assay. After 15 min, the assay was stopped by the addition of 190 μL of malachite green 
solution. The amount of inorganic phosphate released, measured spectrophotometrically at 
700 nm, correlated with the activity of the PDE1. All the results are expressed as the mean of at 
least six experiments ± SEM. The IC50 (concentration inhibiting by 50% the activity of the 
enzyme) values were determined by non-linear regression analysis by fitting to hyperbolic 
inhibition. 
 
4.5. Molecular docking 
 
Docking calculations for compounds 1–7 into the crystal structure of CaM (PDB code: 1A29; 
refined at 2.74 Å) were performed using the autodock 4.0 program.23 Ligands structures were 
constructed using the Spartan 08 software (Wavefunction Inc., Irvine, CA). Hydrogen atoms 
were added and geometry optimization was performed using the PM3 force field. The 
Lamarckian genetic algorithm used to simulate the ligand–receptor docking was first validated 
with the positive controls (TFP and CPZ) dockings of co-crystallized, in both protonated and 
unprotonated forms. These results were in complete agreement with our previous report (data not 
shown).20, 24 Grid dimensions were 60 Å × 60 Å × 60 Å, with a spacing of 0.375 Å between the 
grid points. The docking protocol applied was the following: initial population size of 100, 
random starting position and conformation, translation step ranges of 0.2 Å, rotation step ranges 
of 50 Å, elitism of 0.1, mutation rate of 0.02, crossover rate of 0.8, local search frequency of 
0.06, and 2.5 million energy evaluations. All the rotatable bonds of ligands were allowed to 
rotate during docking simulations. Cluster analysis was performed on the docked results using a 
root mean square (RMS) deviation tolerance of 2.0 Å. All the docking results were sorted by the 
lowest binding energy of the most populated cluster using autodock tools,23 and the top hit from 
each evaluation was selected for further analysis. Optimization of the docked complexes was 
done by energy minimization up to a gradient of 0.01 kcal/mol/Å using the PM3 force field, to 
further refine the autodock output. Binding site residues were selected by a distance for the 
ligand not higher that 6 Å. 
 
4.6. Statistical and data analysis 
 
Data are expressed as the mean of experiments ± SEM for the number (n = 6) of animals used. 
Graphics were plotted and experimental data were adjusted by the nonlinear, curve fitting 
program Microcal® Origin 8.0 (OriginLab, Northampton, MA). Statistical analysis was 
performed by one way analysis of variance (ANOVA) followed by Duncan’s and post-hoc 
Tukey’s tests. p-Values less than 0.05 were considered to be statistically significant. 
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